Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki L. Sato Sells 10,960 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki L. Sato sold 10,960 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total transaction of $137,219.20. Following the sale, the director now owns 1,312,391 shares of the company’s stock, valued at approximately $16,431,135.32. The trade was a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Vir Biotechnology Stock Performance

Shares of VIR stock opened at $12.48 on Thursday. The firm has a market cap of $1.72 billion, a P/E ratio of -3.18 and a beta of 0.51. The firm’s 50 day moving average price is $8.08 and its 200-day moving average price is $8.31. Vir Biotechnology, Inc. has a one year low of $6.56 and a one year high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. During the same quarter last year, the company earned ($1.22) earnings per share. The firm’s revenue for the quarter was down 9.8% on a year-over-year basis. As a group, research analysts predict that Vir Biotechnology, Inc. will post -3.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VIR has been the subject of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. Barclays cut their target price on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.40.

Institutional Trading of Vir Biotechnology

Several hedge funds have recently modified their holdings of VIR. State Street Corp grew its position in shares of Vir Biotechnology by 10.4% during the third quarter. State Street Corp now owns 5,625,533 shares of the company’s stock worth $42,135,000 after buying an additional 530,645 shares in the last quarter. Millennium Management LLC grew its holdings in Vir Biotechnology by 94.6% during the 2nd quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock worth $11,108,000 after acquiring an additional 606,804 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Vir Biotechnology by 13.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock valued at $8,496,000 after purchasing an additional 136,087 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Vir Biotechnology by 0.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock valued at $7,238,000 after purchasing an additional 6,359 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Vir Biotechnology by 10.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock worth $5,673,000 after purchasing an additional 58,360 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).